InfuSystem Holdings, Inc
Close on Oct 19, 2026
- Market cap
- $287.44M
- P/E (TTM)
- 33.5
- Dividend yield
- –
About InfuSystem
Surgical & Medical Instruments & Apparatus, SIC 3841
InfuSystem Holdings, Inc. operates as a healthcare service provider facilitating outpatient care for durable medical equipment manufacturers and healthcare providers. The company provides ambulatory infusion pumps, negative pressure wound therapy devices, related disposable supplies, and biomedical services, including inspection, repair, and certification. Business activities are organized into two operational segments: Patient Services and Device Solutions. Patient Services focuses on clinic-to-home healthcare delivery, continuous chemotherapy infusion, pain management, and wound care, accompanied by third-party billing and clinical support. Device Solutions provides equipment sales, rentals, consumable distribution, and direct biomedical maintenance services to clinical practices. InfuSystem serves hospitals, oncology practices, ambulatory surgery centers, infusion clinics, home care providers, skilled nursing facilities, and acute care facilities.
The company is headquartered in Rochester Hills, Michigan. InfuSystem conducts its business operations across seven locations situated in the United States and Canada, which also house service and repair centers. In addition, the company maintains business relationships with oncologists in approximately 2,100 outpatient oncology clinics and has contracts with nearly 840 third-party payer networks.
Summary of the business section of InfuSystem's latest annual report, written by StockData.
Company profile
Company
- Legal name
- InfuSystem Holdings, Inc
- Founded
- 2005
- Headquarters
- Rochester Hills, MI
- Address
- 3851 West Hamlin Road 48309
- Phone
- (248) 291-1210
- Website
- infusystem.com
- Employees
- 473, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Detroit, Michigan
Stock & identifiers
- Ticker
- INFU
- Exchange
- NYSE
- IPO date
- Apr 12, 2006
- Shares outstanding
- 20M, Jul 31, 2026
- Public float
- $122.27M, Jun 30, 2025
- Filer category
- Accelerated filer<br>Smaller reporting company
- SEC CIK
- 1337013
- CUSIP
- 45685K102
- ISIN
- US45685K1025
- LEI
- 549300F58N8PHJ4QUI59
- EIN
- 20-3341405
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Carrie Lachance | President and CEO, Director | 266,391 |
| Richard Dilorio | Chief Executive Officer, Director | 447,925 |
| Addam Chupa | Executive VP and CIO | 61,160 |
| Jerod Funke | EVP-Chief HR Officer | 29,654 |
| Barry G. Steele | Executive VP and CFO | 121,567 |
| Scott Shuda | Director | 372,383 |
| John J. Sviokla | Director | 10,000 |
| Kenneth D. Eichenbaum | Director | 6,000 |
| Ronald T. Hundzinski | Director | 5,000 |
| Beverly A. Huss | Director | 4,300 |
| Paul Andrew Gendron | Director | 70,000 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Ms. Lachance | $2.91M | $4.47M | $1.27M | $103 | – |
| FY2024 Ms. Lachance | $2.52M | $1.81M | $1.27M | $50 | – |
| FY2023 Ms. Lachance | $2.29M | $2.41M | $1.21M | $62 | – |
| FY2022 Mr. DiIorio | $1.55M | $109.09K | $821.18K | $51 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 473 employees, including 461 full-time employees and 12 part-time or contract employees.”
Corporate history
Events identified from SEC filings